Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...